IP Library Patent Application 15309566
Patent Application
App. No. 15/309,566

WOUND CARE TREATMENT AND METHODS OF MAKING AND USING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/309,566
Abstract

A method of treating a wound including applying a wound care treatment to the wound, the wound care treatment including a preparation composed of morselized amnion tissue and amniotic fluid cells adsorbed to a porous collagen matrix and optionally, glycosaminoglycan. The morselized amnion tissue includes organized amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors contained within the ECM and amniotic tissue cells. The porous collagen matrix is provided as a solid sheet, a meshed or perforated sheet or a flowable material.

Claims (32)

1 . A method of treating a wound comprising:

providing a first preparation including amnion tissue and amniotic fluid cells, wherein the amnion tissue is morselized amnion tissue and includes organized amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors contained within the ECM and amniotic tissue cells,

providing a porous matrix including a mammalian collagen and optionally, glycosaminoglycan (GAG),

combining the first preparation with the porous matrix to form a second preparation, the second preparation including a portion of the first preparation adsorbed to the porous matrix, and

applying the second preparation to a mammal.

2 . The method according to claim 1 wherein the first preparation is combined with the porous matrix to form the second preparation no more than about ten minutes prior to applying the second preparation to the wound.

3 . The method according to claim 1 wherein the ECM includes amnion-derived collagen, fibronectin, laminin, proteoglycans and glycosaminoglycans.

4 . The method according to claim 3 wherein the amnion-derived collagen is derived from an epithelium layer, a basement membrane layer, a compact layer, a fibroblast layer, an intermediate layer and a spongy layer of the amnion tissue.

5 . The method according to claim 1 wherein the mammalian collagen is selected from the group consisting of Type I collagen, Type III collagen, a granulated cross-linked tendon collagen and combinations thereof.

6 . The method according to claim 5 wherein the collagen is provided as a sheet, a meshed sheet or a flowable matrix.

7 . The method according to claim 6 wherein, when the porous matrix is provided as the sheet, the first preparation adsorbs to the sheet in an amount of about 800 μl per square inch of the sheet.

8 . The method according to claim 6 wherein, when the porous matrix is provided as the sheet including the GAG, the first preparation adsorbs to the sheet in an amount of about 300 μl to about 999 μl per square inch of the sheet.

9 . The method according to claim 1 wherein the ground amnion tissue has an average particle size in a range of about 10 micrometers to about 1000 micrometers.

10 . The method according to claim 1 further comprising removing a chorion layer from the amnion tissue.

11 . The method according to claim 1 wherein the second preparation is applied to a skin wound of the mammal thereby promoting healing of the wound.

12 . The method according to claim 11 comprising applying an effective amount of the second preparation to the wound, the effective amount including about 0.05 mg to about 5 mg of amnion tissue per square centimeter of the wound.

13 . The method according to claim 1 wherein an effective amount of the second preparation is applied to a wound surface area, the wound surface area being at least ten times larger than a sum of the surface areas of an amnion side of each piece of the morselized amnion tissue.

14 . A method of treating a wound comprising:

providing a first preparation including amnion tissue and amniotic fluid cells, wherein the amnion tissue is ground amnion tissue and includes amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors and wherein the ECM includes fibronectin, laminin, proteoglycans, glycosaminoglycans and amnion-derived collagen that is derived from an epithelium layer, a basement membrane layer, a compact layer, a fibroblast layer, an intermediate layer and a spongy layer of the amnion tissue,

providing a porous matrix including a processed collagen, wherein the processed collagen is selected from the group consisting of Type I collagen, Type III collagen, a granulated cross-linked tendon collagen and combinations thereof,

combining the first preparation with the porous matrix to form a second preparation, the second preparation including a portion of the first preparation adsorbed to the porous matrix, and

applying the second preparation to the wound no later than 180 minutes after forming the second preparation, whereby the second preparation improves a healing rate of the wound.

15 . The method according to claim 14 comprising providing the porous matrix as a sheet and adsorbing to the sheet between about 300 μl to about 999 μl of the first preparation per square inch of the sheet.

16 . The method according to claim 14 comprising applying an effective amount of the second preparation to the wound, the effective amount including about 0.05 mg to about 5 mg of amnion tissue per square centimeter of the wound

17 . The method according to claim 14 wherein the ground amnion tissue has an average particle size of about 250 micrometers.

18 . A wound treatment comprising:

a porous collagen matrix, and

a preparation adsorbed to the porous collagen matrix, the preparation including amnion tissue and amniotic fluid cells, wherein the amnion tissue is ground amnion tissue and includes amniotic extracellular matrix (ECM), amniotic tissue cells and growth factors and wherein the ECM includes fibronectin, laminin, proteoglycans, glycosaminoglycans and amnion-derived collagen that is derived from an epithelium layer, a basement membrane layer, a compact layer, a fibroblast layer, an intermediate and a spongy layer of the amnion tissue.

19 . The wound treatment according to claim 18 wherein, when the porous collagen matrix is in the form of a sheet, the preparation adsorbs to the sheet in an amount equal to about 300 μl to about 999 μl per square inch of the sheet.

20 . The wound treatment according to claim 18 wherein the ground amnion tissue has an average particle size in a range of 10 micrometers to 1000 micrometers.

21 . The wound treatment according to claim 18 wherein the amnion tissue excludes a chorion layer.

22 . A method of treating a mammal comprising applying the wound treatment of claim 18 to a wound of a mammal thereby promoting healing of the wound.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2026
From: FIRST-CITIZENS BANK & TRUST COMPANY
To: PRIME MERGER SUB, LLC
Reel/Frame 075619/0612 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Recorded Aug 6, 2021
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 057112/0703 →
SECURITY INTEREST Recorded Aug 6, 2021
From: ORGANOGENESIS INC.; PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 057108/0846 →
MERGER AND CHANGE OF NAME Recorded Apr 11, 2019
From: NUTECH MEDICAL, INC.; PRIME MERGER SUB, LLC
To: PRIME MERGER SUB, LLC
Reel/Frame 048860/0093 →
SECURITY INTEREST Recorded Jun 19, 2018
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 046131/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2017
From: NUTECH SPINE, INC.
To: NUTECH MEDICAL, INC.
Reel/Frame 041930/0361 →
SECURITY INTEREST Recorded Mar 28, 2017
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 041767/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2016
From: THOMAS, STEVEN J.; MOWRY, KATIE C.
To: NUTECH SPINE, INC.
Reel/Frame 040253/0989 →